2.06
+0.02(+0.98%)
Currency In USD
| Previous Close | 2.04 |
| Open | 2.04 |
| Day High | 2.08 |
| Day Low | 1.99 |
| 52-Week High | 5.64 |
| 52-Week Low | 1.9 |
| Volume | 570,640 |
| Average Volume | 1.78M |
| Market Cap | 137.04M |
| PE | -2.37 |
| EPS | -0.87 |
| Moving Average 50 Days | 2.5 |
| Moving Average 200 Days | 3.32 |
| Change | 0.02 |
If you invested $1000 in Cardiff Oncology, Inc. (CRDF) 10 years ago, it would be worth $5.42 as of September 28, 2025 at a share price of $2.06. Whereas If you bought $1000 worth of Cardiff Oncology, Inc. (CRDF) shares 5 years ago, it would be worth $169.13 as of September 28, 2025 at a share price of $2.06.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 28, 2025 8:05 PM GMT
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)
GlobeNewswire Inc.
Jul 29, 2025 8:07 PM GMT
– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) – – Early PFS data show a trend favoring 30mg onvansertib dose arm vs. control arm – – Onvansert
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC
GlobeNewswire Inc.
Jun 17, 2025 8:05 PM GMT
– Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development – – Company will hold a conference call on July 29 at